FDA To Review CombinatoRx's Pain Treatment By: MarketMinute.com Stock News September 22, 2009 at 18:26 PM EDT A Food and Drug Administration advisory committee will review CombinatoRx's (Nasdaq: CRXX) pain treatment Exalgo. The stock price dropped 36 cents to close at $1.73.